Jump to content

Cenicriviroc

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 22:02, 9 September 2022 (Dating maintenance tags: {{Cn}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cenicriviroc
Names
Preferred IUPAC name
(5E)-8-[4-(2-Butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
Other names
TAK-652; TBR-652
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1 ☒N
    Key: PNDKCRDVVKJPKG-WHERJAGFSA-N ☒N
  • InChI=1/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1
    Key: PNDKCRDVVKJPKG-WHERJAGFBH
  • O=S(c1ccc(cc1)NC(=O)\C4=C\c3c(ccc(c2ccc(OCCOCCCC)cc2)c3)N(CCC4)CC(C)C)Cc5cncn5CCC
Properties
C41H52N4O4S
Molar mass 696.95 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Cenicriviroc (INN,[1] code names TAK-652, TBR-652, commonly abbreviated as CVC) is an experimental drug candidate for the treatment of HIV infection[2] and in combination with Tropifexor for non-alcoholic steatohepatitis.[3] It is being developed by Takeda and Tobira Therapeutics.

Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors,[4] allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Inhibition of CCR2 may have an anti-inflammatory effect.[citation needed]

A double-blind, randomized, placebo-controlled clinical study to assess the antiviral activity, safety, and tolerability of cenicriviroc was conducted in 2010. HIV-infected patients taking cenicriviroc had significant reductions in viral load, with the effect persisting up to two weeks after discontinuation of treatment.[5] Additional Phase II clinical trials are underway.[6][when?]

Cenicriviroc is also in two separate clinical trials for COVID-19: the ACTIV-I trial run by the National Center for Advancing Translational Sciences, where it is compared with a number of other immunomodulatory agents,[7] and the Charité Trial of Cenicriviroc at the Charité Hospital in Berlin.[8] As of 2 July 2021, both trials are recruiting participants, and are expected to complete in September 2021.[citation needed]

Phase IIb data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in March 2013 showed similar viral suppression rates of 76% for patients taking 100 mg cenicriviroc, 73% with 200 mg cenicriviroc, and 71% with efavirenz. Non-response rates were higher with cenicriviroc, however, largely due to greater drop-out of patients. A new tablet formulation with lower pill burden may improve adherence. Looking at immune and inflammatory biomarkers, levels of MCP-1 increased and soluble CD14 decreased in the cenicriviroc arms.[9]

See also

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. 2011. pp. 53–4. Retrieved 25 November 2016.
  2. ^ Klibanov, OM; Williams, SH; Iler, CA (August 2010). "Cenicriviroc, an Orally Active CCR5 Antagonist for the Potential Treatment of HIV Infection". Current Opinion in Investigational Drugs. 11 (8): 940–50. PMID 20721836.
  3. ^ "A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis". 21 January 2022.
  4. ^ Baba, M; Takashima, K; Miyake, H; Kanzaki, N; Teshima, K; Wang, X; Shiraishi, M; Iizawa, Y (26 October 2005). "TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans". Antimicrobial Agents and Chemotherapy. 49 (11): 4584–91. doi:10.1128/AAC.49.11.4584-4591.2005. PMC 1280155. PMID 16251299.
  5. ^ Reviriego, C (July 2011). "Chemokine CCR2/CCR5 Receptor Antagonist Anti-HIV Agent". Drugs of the Future. 36 (7): 511–7. doi:10.1358/dof.2011.036.07.1622066.
  6. ^ "Tobira Therapeutics Initiates Phase 2b Trial of Cenicriviroc". The Body. July 5, 2011.
  7. ^ Benjamin, Daniel (2021-06-29). "Randomized Master Protocol for Immune Modulators for Treating COVID-19". Daniel Benjamin, National Center for Advancing Translational Science (NCATS), Biomedical Advanced Research and Development Authority. {{cite journal}}: Cite journal requires |journal= (help)
  8. ^ Tacke, Frank (2020-08-25). "Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients". Charite University, Berlin, Germany, Allergan. {{cite journal}}: Cite journal requires |journal= (help)
  9. ^ CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects. Highleyman, Liz. HIVandHepatitis.com. 7 March 2013.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cenicriviroc&oldid=1109445228"